GlassScriptPhysician profile
Beverly F Gilder
NPI 1871658393
$557,961.90
in general payments reported to CMS, 2019-2025
71 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $48K · 2021: $83K · 2022: $62K · 2023: $61K · 2024: $79K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Food and Beverage: $27K · Consulting Fee: $16K · Travel and Lodging: $3,618 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,666.25 |
| Food and Beverage | $27,228.58 |
| Consulting Fee | $15,694.00 |
| Travel and Lodging | $3,617.97 |
| Education | $115.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $187,482.40 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Biogen, INC. | $175,300.24 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Genzyme Corporation | $76,211.66 | 2019-2025 | |
| Tg Therapeutics, INC. | $49,444.42 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $14,074.52 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $11,111.39 | 2019-2025 | |
| Celgene Corporation | $8,576.70 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $7,392.11 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $7,065.79 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $4,931.92 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Abbvie INC. | $3,223.94 | 2021-2025 | |
| Ucb, INC. | $1,629.50 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Pfizer INC. | $1,227.79 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $878.67 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Neurocrine Biosciences, INC. | $689.49 | 2019-2025 | Ingrezza, Ongentys |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $474.68 | 2020-2025 | Acthar |
| Lundbeck LLC | $468.48 | 2019-2025 | Vyepti |
| Sk Life Science, INC. | $440.66 | 2022-2025 | |
| Argenx US, INC. | $422.99 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $416.47 | 2019-2022 | |
| Lilly USA, LLC | $363.04 | 2019-2023 | Emgality, Reyvow |
| Merz Pharmaceuticals, LLC | $350.77 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Tanabe Pharma America, INC. | $328.21 | 2022-2024 | |
| Neurelis, INC. | $306.07 | 2022-2025 | Valtoco |
| Horizon Therapeutics Plc | $286.98 | 2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $286.40 | 2019-2025 | Rytary, Crexont |
| Ani Pharmaceuticals, INC. | $283.00 | 2022-2024 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $271.31 | 2024-2025 | Ponvory |
| Axsome Therapeutics, INC. | $250.44 | 2023-2025 | Symbravo, Sunosi |
| Mallinckrodt Enterprises LLC | $234.54 | 2019 | |
| Mdd US Operations, LLC | $219.42 | 2022-2025 | Gocovri, Gocovri, Qelbree |
| Banner Life Sciences, LLC | $214.46 | 2021-2024 | |
| Acorda Therapeutics, INC | $209.93 | 2021-2023 | Inbrija |
| Biohaven Pharmaceuticals, INC. | $208.31 | 2021 | |
| Upsher-Smith Laboratories LLC | $202.63 | 2019-2022 | |
| Medtronic USA, INC. | $182.83 | 2019 | |
| Assertio Therapeutics, INC. | $182.50 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $152.42 | 2022-2025 | Fycompa, Firdapse |
| Jazz Pharmaceuticals INC. | $143.39 | 2022-2024 | Epidiolex, Xywav |
| Scilex Pharmaceuticals INC. | $134.25 | 2019-2024 | Ztlido |
| Supernus Pharmaceuticals, INC. | $125.94 | 2019-2022 | |
| Boston Scientific Corporation | $111.98 | 2023-2025 | Vercise, Wavewriter Alpha Prime 16 |
| Eisai INC. | $110.49 | 2022-2024 | |
| Kyowa Kirin, INC. | $103.79 | 2019-2024 | Nourianz |
| Amylyx Pharmaceuticals, INC. | $102.26 | 2023 | Relyvrio |
| Avanir Pharmaceuticals, INC. | $95.94 | 2019-2020 | |
| Bausch Health US, LLC | $81.03 | 2019-2020 | |
| Promius Pharma LLC | $79.93 | 2019 | |
| Springworks Therapeutics, INC. | $73.80 | 2025 | Gomekli |
| Acadia Pharmaceuticals INC | $73.11 | 2023-2025 | Nuplazid |
| Zyla Life Sciences, INC. | $72.05 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.34 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $69.01 | 2024-2025 | Dysport |
| Csl Behring | $59.30 | 2025 | Hizentra, Privigen |
| Otsuka America Pharmaceutical, INC. | $53.29 | 2023-2024 | Nuedexta |
| Janssen Pharmaceuticals, INC | $50.26 | 2021 | |
| Cycle Pharmaceuticals INC | $44.21 | 2025 | Tascenso Odt, Bafiertam |
| Janssen Biotech, INC. | $39.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $32.01 | 2025 | Wainua |
| Immedica Pharma US, INC. | $30.48 | 2023 | |
| Ge Healthcare | $29.99 | 2020 | |
| Avion Pharmaceuticals | $25.51 | 2023 | Dhivy |
| Averitas Pharma INC. | $22.61 | 2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $20.29 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.42 | 2023 | Keveyis |
| Abbott Laboratories | $18.11 | 2022 | |
| Merck Sharp & Dohme LLC | $14.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.66 | 2020 | |
| Biotronik INC. | $14.38 | 2022 | |
| Sumitomo Pharma America, INC. | $14.17 | 2023 | Aptiom |
| Idorsia Pharmaceuticals US INC | $13.18 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Gilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.